title: Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
abstract: OBJECTIVE
  The purpose of this study was to determine whether early qualitative or quantitative angiographic features can predict reocclusion after initially successful coronary thrombolysis.
  
  
  BACKGROUND
  Although both the benefits of early reperfusion and the consequences of subsequent reocclusion after thrombolysis for acute myocardial infarction have been well described, efforts to describe angiographic markers of lesions at high risk for reocclusion have produced conflicting results. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) angiographic trial provides the opportunity to examine these relations in the largest single, prospective patient cohort studied to date.
  
  
  METHODS
  We studied 559 patients undergoing follow-up angiography at 90 min and 5 to 7 days after thrombolysis in the GUSTO trial. Patients received one of four thrombolytic regimens: 1) streptokinase with intravenous heparin; 2) streptokinase with subcutaneous heparin; 3) accelerated-dose recombinant tissue-type plasminogen activator (rt-PA) with intravenous heparin; or 4) a combination of streptokinase and conventionally dosed rt-PA with intravenous heparin. Qualitative variables examined at 90-min angiography included Thrombolysis in Myocardial Infarction (TIMI) flow grade, visible thrombus and lesion morphology. Quantitative variables included percent diameter stenosis, percent area stenosis, minimal lumen diameter and lesion length. The study contained a power > 0.85 to detect clinically important differences in percent diameter stenosis, percent area stenosis and minimal lumen diameter between the groups with subsequent reocclusion and sustained patency at the p = 0.05 level.
  
  
  RESULTS
  At follow-up, 33 patients (5.9%) had reocclusion. The reocclusion rate for patients with early TIMI grade 2 flow was 6.3% versus 5.6% for TIMI grade 3 flow (p = NS). When the group with reocclusion was compared with the group with continued patency, there were no differences in presence of early visible thrombus, complex lesion morphology, percent diameter stenosis, percent area stenosis, minimal lumen diameter or lesion length.
  
  
  CONCLUSIONS
  Our findings demonstrate that neither qualitative nor quantitative angiographic variables at 90 min after initiation of thrombolytic therapy can be used to predict subsequent coronary reocclusion.
authors.affiliation: Division of Cardiology, George Washington University, Washington, D.C. 20037.
authors.forename: J S
authors.initials: JS
authors.lastname: Reiner
authors.forename: C F
authors.initials: CF
authors.lastname: Lundergan
authors.forename: M
authors.initials: M
authors.lastname: van den Brand
authors.forename: J
authors.initials: J
authors.lastname: Boland
authors.forename: M A
authors.initials: MA
authors.lastname: Thompson
authors.forename: J
authors.initials: J
authors.lastname: Machecourt
authors.forename: A
authors.initials: A
authors.lastname: Py
authors.forename: G S
authors.initials: GS
authors.lastname: Pilcher
authors.forename: C A
authors.initials: CA
authors.lastname: Fink
authors.forename: J R
authors.initials: JR
authors.lastname: Burton
mesh_terms: D000368:Aged; D017023:Coronary Angiography / Q000379:methods; D004359:Drug Therapy, Combination; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging* / Q000188:drug therapy; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D012008:Recurrence; D015203:Reproducibility of Results; D013300:Streptokinase / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000379:methods; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D006493:Heparin; D013300:Streptokinase; D010959:Tissue Plasminogen Activator